Loading...
Market
What will be the sales figures for Eli Lilly's once-weekly insulin efsitora alfa by end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Eli Lilly's financial reports and earnings announcements
Story
Eli Lilly's Once-Weekly Insulin Shows Positive A1C Reductions in Phase 3 Trials
Sep 5, 2024, 10:57 AM
Eli Lilly announced positive topline data from its QWINT-1 and QWINT-3 Phase 3 clinical trials evaluating once-weekly insulin efsitora alfa in adults with type 2 diabetes. The trials demonstrated that the insulin led to non-inferior A1C reductions similar to daily insulin regimens, meeting their primary endpoints. This fixed dose study is the first of its kind, showcasing the potential of once-weekly insulin treatments for diabetes management.
View original story
Similar markets
Less than 500,000 units • 25%
500,000 to 1 million units • 25%
1 million to 2 million units • 25%
More than 2 million units • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Other • 25%
Yes • 50%
No • 50%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Mounjaro • 25%
Zepbound • 25%
Trulicity • 25%
Humalog • 25%